Glaxo Group Limited

Allen Hanburys Limited

Roger F Newton

Harry Finch

Eric W Collington

Christopher J Wallis

David I Scopes

Stanley M Roberts

David K Rainey

Richard C Cookson

Deryck Rhodes

Michael J Dimsdale

Compounds of general formula (I): ##STR1## wherein R is a chlorine, bromine or iodine atom and physiologically acceptable salts thereof with bases of use as antiviral agents.

5-Halovinyl-2'-deoxyuridine derivatives

Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH--or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.

Prostanoid compounds and pharmaceutical compositions

Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.

Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester grup; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.

Prostanoid compounds and compositions

The stereospecific alkylation of a novel 3-endo-protected hydroxyl-tricyclo[3,2,0,0.sup.2,7 ]heptan-6-one is described using a range of lithium-, copper or magnesium-containing organometallic reagents. This reaction provides a 5-endo-protected hydroxyl-bicyclo[2,2,1]-heptan-2-one system from which prostaglandin compounds of the F series having a protecting group at the 9-position hydroxyl group may readily be obtained by a sequence of reactions.

5-Endo-protected hydroxyl-bicyclo[2,2,1]-heptan-2-ones and process for

Compounds of the general formula I: ##STR1## in which R.sub.1 represents cycloalkyl, aralkyl, heterocyclic aryl, or substituted phenyl, in which the substituents on the phenyl group are one or more of the following groups, that is halogen, hydroxy, alkoxy (C.sub.1 -C.sub.4), alkyl (C.sub.1 -C.sub.4), nitro, dialkylamino or methylenedioxy;

Growing community of inventors

Melbourn, United Kingdom

Roger F Newton